Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 807-272-7 | CAS number: 7182-21-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- The study was conducted between 07 Jul 2014 and 06 August 2014.
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study is considered to be a reliability 1 as it has been conducted according to OECD Test Guideline 423 using an acute toxic class method and in compliance with GLP.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 014
- Report date:
- 2014
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- 3-methyl-1-benzofuran-5-ol
- EC Number:
- 807-272-7
- Cas Number:
- 7182-21-0
- Molecular formula:
- C9H8O2
- IUPAC Name:
- 3-methyl-1-benzofuran-5-ol
- Test material form:
- other: Solid
- Details on test material:
- Identification: IFF TM 11-0230
Batch: PJ226-66
Purity: >99%
Physical state / Appearance: beige solid
Expiry date: 01 May 2015
Storage Conditions: Room temperature in the dark
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Female Wistar (RccHan™:WIST) strain rats were supplied by Harlan Laboratories UK Ltd., Oxon, UK. On receipt the animals were randomly allocated to cages. The females were nulliparous and non pregnant. After an acclimatization period of at least five days the animals were selected at random and given a number unique within the study by indelible ink marking on the tail and a number written on a cage card. At the start of the study the animals were eight to twelve weeks of age. The body weight variation did not exceed ±20% of the mean body weight of the initially dosed group.
The animals were housed in groups of three in suspended solid floor polypropylene cages furnished with woodflakes. With the exception of an overnight fast immediately before dosing and for approximately three to four hours after dosing, free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK) was allowed throughout the study. The diet, drinking water and bedding were routinely analyzed and were considered not to contain any contaminants that would reasonably be expected to affect the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25 °C and 30 to 70% respectively. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give twelve hours continuous light (06:00 to 18:00) and twelve hours darkness.
The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study.
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- DMSO
- Details on oral exposure:
- For the purpose of the study the test item was freshly prepared, as required, as a solution in dimethyl sulphoxide. Dimethyl sulphoxide was used because the test item did not dissolve/suspend in distilled water or arachis oil BP.
The test item was formulated within two hours of being applied to the test system. It is assumed that the formulation was stable for this duration.
No analysis was conducted to determine the homogeneity, concentration or stability of the test item formulation. This is an exception with regard to GLP and has been reflected in the GLP compliance statement. - Doses:
- 300 and 2000 mg/kg.
- No. of animals per sex per dose:
- 3 females per dose.
- Control animals:
- no
- Details on study design:
- In the absence of data regarding the toxicity of the test item, 300 mg/kg was chosen as the starting dose.
All animals were dosed once only by gavage, using a metal cannula attached to a graduated syringe. The volume administered to each animal was calculated according to the fasted body weight at the time of dosing. Treatment of animals was sequential. Sufficient time was allowed between each group to confirm the survival of the previously dosed animals.
The animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing and subsequently once daily for up to fourteen days.
Individual body weights were recorded prior to dosing and seven and fourteen days after treatment or at death.
At the end of the observation period the surviving animals were killed by cervical dislocation. All animals were subjected to gross pathological examination. This consisted of an external examination and opening of the abdominal and thoracic cavities for examination of major organs. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.
Results and discussion
Effect levels
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- 1 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- Two animals treated at a dose level of 2000 mg/kg were found dead during the day of dosing. There were no deaths at a dose level of 300 mg/kg.
- Clinical signs:
- Signs of systemic toxicity noted at a dose level of 2000 mg/kg were increased salivation, noisy respiration, increased respiratory rate, prostration, occasional body tremors, hunched posture and pilo erection. The surviving animal treated at a dose level of 2000 mg/kg appeared normal 4 days after dosing.
Signs of systemic toxicity noted during the day of dosing in the initial group of animals treated at a dose level of 300 mg/kg were hunched posture, ataxia and pilo erection. There were no signs of systemic toxicity noted in the second group of animals treated at a dose level of 300 mg/kg. - Body weight:
- Surviving animals showed expected gains in body weight over the observation period.
- Gross pathology:
- Abnormalities noted at necropsy of animals treated at a dose level of 2000 mg/kg that died during the study were brown liquid present in the stomach and epithelial sloughing and/or hemorrhage of the gastric mucosa. No abnormalities were noted at necropsy of animals that were killed at the end of the study.
Any other information on results incl. tables
Mortality data
Dose Level mg/kg |
Sex |
Number of Animals Treated |
Deaths During Day of Dosing |
Deaths During Period After Dosing |
Deaths |
||||||||||
½ |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8-14 |
||||
300 |
Female |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0/3 |
Female |
3 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0/3 |
|
2000 |
Female |
3 |
1 |
1 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
2/3 |
Individual clinical observations - 300 mg/kg
Dose Level mg/kg |
Animal Number and Sex |
Effects Noted After Dosing |
Effects Noted During Period After Dosing |
||||||||||||||||
½ |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
300 |
1-0 Female |
0 |
H |
H |
H |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1-1 Female |
0 |
H |
H |
H |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
1-2 Female |
0 |
HP |
HPA |
HA |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-0 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-1 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
|
3-2 Female |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No signs of systemic toxicity
H = Hunched posture
P = Pilo‑erection
A = Ataxia
Individual clinical observations - 2000 mg/kg
Dose Level mg/kg |
Animal Number and Sex |
Effects Noted After Dosing |
Effects Noted During Period After Dosing |
||||||||||||||||
½ |
1 |
2 |
4 |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
11 |
12 |
13 |
14 |
||
2000 |
2-0 Female |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2-1 Female |
SRnPrTo |
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2-2 Female |
HPSRn |
HPRn |
HPRn |
HRn |
HRnRi |
HRn |
H |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 = No signs of systemic toxicity
H = Hunched posture
P = Pilo‑erection
Pr = Prostration
Ri = Increased respiratory rate
Rn =Noisy respiration
S = Increased salivation
To = Occasional body tremors
X = Animal dead
Individual Body Weights and Body Weight Changes - 300 mg/kg
Dose Level mg/kg |
Animal Number |
Body Weight (g) at Day |
Body Weight Gain (g) During Week |
|||
0 |
7 |
14 |
1 |
2 |
||
300 |
1-0 Female |
175 |
201 |
211 |
26 |
10 |
1-1 Female |
187 |
204 |
215 |
17 |
11 |
|
1-2 Female |
179 |
193 |
196 |
14 |
3 |
|
3-0 Female |
163 |
184 |
195 |
21 |
11 |
|
3-1 Female |
155 |
175 |
184 |
20 |
9 |
|
3-2 Female |
150 |
177 |
188 |
27 |
11 |
Individual Body Weights and Body Weight Changes - 2000 mg/kg
Dose Level mg/kg |
Animal Number and Sex |
Body Weight (g) at Day |
Body Weight (g) |
Body Weight Gain (g) During Week |
|||
0 |
7 |
14 |
1 |
2 |
|||
2000 |
2-0 Female |
158 |
- |
- |
155 |
- |
- |
2-1 Female |
150 |
- |
- |
149 |
- |
- |
|
2-2 Female |
157 |
159 |
187 |
|
2 |
28 |
Individual Necropsy Findings - 300 mg/kg
Dose Level |
Animal Number |
Time of Death |
Macroscopic Observations |
300 |
1-0 Female |
Killed Day 14 |
No abnormalities detected |
1-1 Female |
Killed Day 14 |
No abnormalities detected |
|
1-2 Female |
Killed Day 14 |
No abnormalities detected |
|
3-0 Female |
Killed Day 14 |
No abnormalities detected |
|
3-1 Female |
Killed Day 14 |
No abnormalities detected |
|
3-2 Female |
Killed Day 14 |
No abnormalities detected |
Individual Necropsy Findings - 2000 mg/kg
Dose Level |
Animal Number |
Time of Death |
Macroscopic Observations |
2000 |
2-0 Female |
Found dead Day 0 |
Stomach: brown liquid present Gastric mucosa: hemorrhage epithelial sloughing |
2-1 Female |
Found dead Day 0 |
Stomach: brown liquid present Gastric mucosa: hemorrhage |
|
2-2 Female |
Killed Day 14 |
No abnormalities detected |
Applicant's summary and conclusion
- Interpretation of results:
- Toxicity Category IV
- Remarks:
- Migrated information Criteria used for interpretation of results: EU
- Conclusions:
- The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was approximately 1000 mg/kg body weight (Globally Harmonized Classification System – Category 4, >300 - 2000 mg/kg body weight).
The test item was also classified as Category 4 according to Regulation (EC) No. 1272/2008, relating to the Classification, Labelling and Packaging of Substances and Mixtures. It is reasonable to assume that the Signal Word “Warning” and the Hazard Statement “H302: Harmful if swallowed” are therefore required. - Executive summary:
The acute oral toxicity of the test substance, TM 11-0230, was assessed according to OECD Test Guideline 423 using an acute toxic class method.
In this study, 3 female rats were administered to the substance at the dose level of 300 mg/kg bw.No mortality occurred. Based on the results from 300 mg/kg, furhter groups of rats were treated at dose of levels of 300 and 2000 mg/kg. Two animals treated at a dose of 2000 mg/kg were found dead during the day of doseing. There were no death at a dose of level of 300 mg/kg. Signs of systemic toxicity noted at a dose of 2000 mg/kg were increased salivation, noisy respiration, increased respiration rate, prostration, occasional body tremors, hunched posture and piloerection. Signs of systemic toxicity noted in teh initial group of animals treated at a dose of 300 mg/kg were hunched posture, ataxia and piloerection. There were no signs of systemic toxicity noted in the second groups dosed at level of 300 mg/kg.The surviving animals showed expected body weight gain. Abnormalities noted at necropsy of animals treated at a dose of 2000 mg/kg that died during the study were brown liquid present in teh stomach and epithelial sloughing and/or hemorrhage of the gastric mucosa. No abnormalities were noted at necropsy of surviving animals.
The acute oral median lethal dose (LD50) of the test item in the female Wistar strain rat was approximately 1000 mg/kg body weight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.